Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Celcuity, Inc. (CELC : NSDQ)

• Company Description    Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. Number of Employees: 155

• Price / Volume Information    Yesterday's Closing Price: $138.23 Daily Weekly Monthly 20 Day Moving Average: 1,255,151 shares Shares Outstanding: 48.77 (millions) Market Capitalization: $6,740.92 (millions) Beta: 0.09 52 Week High: $151.02 52 Week Low: $10.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 21.72% 15.78% 12 Week 24.40% 15.00% Year To Date 38.59% 31.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2800 CAMPUS DRIVE SUITE 140 - MINNEAPOLIS,MN 55441 USA ph: 763-392-0123 fax: - None http://www.celcuity.com

• General Corporate Information    Officers Brian F. Sullivan - Chief Executive Officer and Chairman Vicky Hahne - Chief Financial Officer Richard E. Buller - Director Dave F. Dalvey - Director Leo T. Furcht - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15102K100 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 48.77 Most Recent Split Date: (:1) Beta: 0.09 Market Capitalization: $6,740.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.18 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 125.94 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -12.79% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -244.61 12/31/25 - -203.17 09/30/25 - -179.00 ROA 03/31/26 - -50.22 12/31/25 - -52.68 09/30/25 - -57.97 Current Ratio 03/31/26 - 12.31 12/31/25 - 10.55 09/30/25 - 12.26 Quick Ratio 03/31/26 - 12.31 12/31/25 - 10.55 09/30/25 - 12.26 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.10 12/31/25 - 2.17 09/30/25 - 2.76 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 6.04 12/31/25 - 3.20 09/30/25 - 2.74 Debt-to-Capital 03/31/26 - 85.80 12/31/25 - 76.19 09/30/25 - 73.25

Powered by Zacks Investment Research ©